Activity from announced rounds
Gaingels co-invests alongside venture leads in companies committed to diverse and inclusive teams, spanning seed through growth and pre-IPO rounds across technology, healthcare and consumer markets.
Its investor community includes LGBTQ+ people and allies, extending representation within the ownership of venture-backed companies. Portfolio companies work with its Gaingels Letter commitments and Venture Inclusion programme on building more inclusive organisations.
A board access programme provides free recruitment advice for diverse board members and observers. This gives founders a practical governance resource alongside a co-investment partner for a round led by another venture firm.
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy
Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2
Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners.